Refine
Has Fulltext
- yes (23)
Is part of the Bibliography
- yes (23)
Document Type
- Journal article (23) (remove)
Language
- English (23)
Keywords
- theranostics (7)
- Positronen-Emissions-Tomografie (5)
- prostate cancer (5)
- neuroendocrine tumor (4)
- CXCR4 (3)
- PET (3)
- PET/CT (3)
- PSMA (3)
- positron emission tomography (3)
- MRI (2)
- PRRT (2)
- PSMA-RADS (2)
- Prostate Cancer (2)
- RADS (2)
- kidney (2)
- molecular imaging (2)
- norepinephrine transporter (2)
- peptide receptor radionuclide therapy (2)
- prostate-specific membrane antigen (2)
- prostate-specific membrane antigen (PSMA) (2)
- radioligand therapy (2)
- reporting and data system (2)
- somatostatin receptor (2)
- somatostatin receptor (SSTR) (2)
- 18F-DCFPL (1)
- 18F-DCFPyL (1)
- 18F-FDS (1)
- 2-deoxy-2-18F-fluoro-D-sorbitol (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AI (1)
- CTCAE (1)
- DCGAN (1)
- GAN (1)
- GCA (1)
- Ganglia (1)
- Gleason score (1)
- Imaging pitfalls (1)
- Magnetresonanztomografie (1)
- Myocardial-perfusion SPECT (1)
- NEC (1)
- NET (1)
- PMR (1)
- PSMA-PET (1)
- Pentixafor (1)
- Pitfall (1)
- Positron Emission Tomography (1)
- Positron-Emission Tomography (1)
- Prostata (1)
- RLT (1)
- Radiofluorine (1)
- Radiotracer (1)
- SSTR-PET (1)
- SSTR-RADS (1)
- SUV (1)
- Sodium-Glucose Cotransporters (SGLTs) (1)
- T-shaped π-π stacking (1)
- Tracer (1)
- Virchow Node (1)
- [18F]FDG PET/CT (1)
- [68Ga]DOTATOC (1)
- [68Ga]Pentixafor (1)
- \(^{177}\)Lu (1)
- \(^{18}\)F (1)
- \(^{18}\)F-DCFPyL PET/CT (1)
- \(^{18}\)F-PSMA-1007 (1)
- \(^{68}\)Ga (1)
- artificial intelligence (1)
- cardiac innervation imaging (1)
- chemokine receptor (1)
- diabetes (1)
- ejection fraction (1)
- giant cell arteritis (1)
- glomerular filtration rate (1)
- hematotoxicity (1)
- inflammation (1)
- left-ventricular function (1)
- machine learning (1)
- magnetic resonance imaging (1)
- meningioma (1)
- nephrology (1)
- nephrotoxicity (1)
- neuroblastoma (1)
- neuroendocrine neoplasms (NEN) (1)
- neuroendocrine tumors (NET) (1)
- nonhuman primates (1)
- personalized medicine (1)
- polymyalgia rheumatica (1)
- prostate-specific antigen (1)
- quantification (1)
- radiotracer kinetics (1)
- rats (1)
- renal (1)
- renal function (1)
- renal imaging (1)
- reporting and data systems (1)
- solid tumors (1)
- split renal function (1)
- staging (1)
- standardization (1)
- standardized reporting system (1)
- stroke (1)
- sympathetic nervous system (1)
- urology (1)
- vasculature (1)
- vasculitis (1)
- vestibular schwannoma (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (23) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (7)
Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with \(^{68}\)Ga-labeled compounds has rapidly become adopted as part of routine clinical care in many parts of the world. However, recent years have witnessed the start of a shift from \(^{68}\)Ga- to \(^{18}\)F-labeled PSMA-targeted compounds. The latter imaging agents have several key advantages, which may lay the groundwork for an even more widespread adoption into the clinic. First, facilitated delivery from distant suppliers expands the availability of PET radiopharmaceuticals in smaller hospitals operating a PET center but lacking the patient volume to justify an onsite \(^{68}\)Ge/\(^{68}\)Ga generator. Thus, such an approach meets the increasing demand for PSMA-targeted PET imaging in areas with lower population density and may even lead to cost-savings compared to in-house production. Moreover, \(^{18}\)F-labeled radiotracers have a higher positron yield and lower positron energy, which in turn decreases image noise, improves contrast resolution, and maximizes the likelihood of detecting subtle lesions. In addition, the longer half-life of 110 min allows for improved delayed imaging protocols and flexibility in study design, which may further increase diagnostic accuracy. Moreover, such compounds can be distributed to sites which are not allowed to produce radiotracers on-site due to regulatory issues or to centers without access to a cyclotron. In light of these advantageous characteristics, \(^{18}\)F-labeled PSMA-targeted PET radiotracers may play an important role in both optimizing this transformative imaging modality and making it widely available. We have aimed to provide a concise overview of emerging \(^{18}\)F-labeled PSMA-targeted radiotracers undergoing active clinical development. Given the wide array of available radiotracers, comparative studies are needed to firmly establish the role of the available \(^{18}\)F-labeled compounds in the field of molecular PCa imaging, preferably in different clinical scenarios.
We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [\(^{68}\)Ga]Pentixafor.
Methods: 4 patients with 6 primarily diagnosed or pre-treated/observed VS were enrolled. All subjects underwent [\(^{68}\)Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients.
Results: [\(^{68}\)Ga]Pentixafor PET/CT was visually positive in all cases. SUV\(_{mean}\) and SUV\(_{max}\) were 3.0 ± 0.3 and 3.8 ± 0.4 and TBR\(_{mean}\) and TBR\(_{max}\) were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors.
Conclusion: Non-invasive imaging of CXCR4 expression using [\(^{68}\)Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.